vs
AXCELIS TECHNOLOGIES INC（ACLS）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
Penumbra Inc的季度营收约是AXCELIS TECHNOLOGIES INC的1.6倍（$385.4M vs $238.3M），AXCELIS TECHNOLOGIES INC净利率更高（14.4% vs 12.3%，领先2.1%），Penumbra Inc同比增速更快（22.1% vs -5.6%），Penumbra Inc自由现金流更多（$68.0M vs $-8.9M），过去两年Penumbra Inc的营收复合增速更高（17.6% vs -2.8%）
Axcelis Technologies是一家美国半导体设备供应商，1995年成立，总部位于美国马萨诸塞州贝弗利。公司面向全球半导体制造行业，从事半导体生产核心设备的设计、制造及服务，主营产品包括高中电流、高能离子注入系统以及半导体芯片制造用固化系统。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
ACLS vs PEN — 直观对比
营收规模更大
PEN
是对方的1.6倍
$238.3M
营收增速更快
PEN
高出27.7%
-5.6%
净利率更高
ACLS
高出2.1%
12.3%
自由现金流更多
PEN
多$77.0M
$-8.9M
两年增速更快
PEN
近两年复合增速
-2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $238.3M | $385.4M |
| 净利润 | $34.3M | $47.3M |
| 毛利率 | 47.0% | 68.0% |
| 营业利润率 | 15.2% | 15.4% |
| 净利率 | 14.4% | 12.3% |
| 营收同比 | -5.6% | 22.1% |
| 净利润同比 | -31.3% | 40.6% |
| 每股收益（稀释后） | $1.11 | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLSPEN
| Q4 25 | $238.3M | $385.4M | ||
| Q3 25 | $213.6M | $354.7M | ||
| Q2 25 | $194.5M | $339.5M | ||
| Q1 25 | $192.6M | $324.1M | ||
| Q4 24 | $252.4M | $315.5M | ||
| Q3 24 | $256.6M | $301.0M | ||
| Q2 24 | $256.5M | $299.4M | ||
| Q1 24 | $252.4M | $278.7M |
净利润ACLSPEN
| Q4 25 | $34.3M | $47.3M | ||
| Q3 25 | $26.0M | $45.9M | ||
| Q2 25 | $31.4M | $45.3M | ||
| Q1 25 | $28.6M | $39.2M | ||
| Q4 24 | $50.0M | $33.7M | ||
| Q3 24 | $48.6M | $29.5M | ||
| Q2 24 | $50.9M | $-60.2M | ||
| Q1 24 | $51.6M | $11.0M |
毛利率ACLSPEN
| Q4 25 | 47.0% | 68.0% | ||
| Q3 25 | 41.6% | 67.8% | ||
| Q2 25 | 44.9% | 66.0% | ||
| Q1 25 | 46.1% | 66.6% | ||
| Q4 24 | 46.0% | 66.8% | ||
| Q3 24 | 42.9% | 66.5% | ||
| Q2 24 | 43.8% | 54.4% | ||
| Q1 24 | 46.0% | 65.0% |
营业利润率ACLSPEN
| Q4 25 | 15.2% | 15.4% | ||
| Q3 25 | 11.7% | 13.8% | ||
| Q2 25 | 14.9% | 12.0% | ||
| Q1 25 | 15.1% | 12.4% | ||
| Q4 24 | 21.6% | 13.6% | ||
| Q3 24 | 18.3% | 11.7% | ||
| Q2 24 | 20.6% | -27.0% | ||
| Q1 24 | 22.4% | 4.3% |
净利率ACLSPEN
| Q4 25 | 14.4% | 12.3% | ||
| Q3 25 | 12.2% | 12.9% | ||
| Q2 25 | 16.1% | 13.3% | ||
| Q1 25 | 14.8% | 12.1% | ||
| Q4 24 | 19.8% | 10.7% | ||
| Q3 24 | 18.9% | 9.8% | ||
| Q2 24 | 19.8% | -20.1% | ||
| Q1 24 | 20.4% | 3.9% |
每股收益（稀释后）ACLSPEN
| Q4 25 | $1.11 | $1.20 | ||
| Q3 25 | $0.83 | $1.17 | ||
| Q2 25 | $0.98 | $1.15 | ||
| Q1 25 | $0.88 | $1.00 | ||
| Q4 24 | $1.54 | $0.88 | ||
| Q3 24 | $1.49 | $0.75 | ||
| Q2 24 | $1.55 | $-1.55 | ||
| Q1 24 | $1.57 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $374.3M | $186.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $1.4B |
| 总资产 | $1.4B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLSPEN
| Q4 25 | $374.3M | $186.9M | ||
| Q3 25 | $449.6M | $321.0M | ||
| Q2 25 | $549.8M | $421.8M | ||
| Q1 25 | $587.1M | $376.1M | ||
| Q4 24 | $571.3M | $324.4M | ||
| Q3 24 | $579.4M | $280.5M | ||
| Q2 24 | $548.3M | $288.3M | ||
| Q1 24 | $530.2M | $223.1M |
股东权益ACLSPEN
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $975.6M | $1.1B | ||
| Q2 24 | $934.9M | $1.2B | ||
| Q1 24 | $901.7M | $1.2B |
总资产ACLSPEN
| Q4 25 | $1.4B | $1.8B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.7B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.3B | $1.5B | ||
| Q1 24 | $1.3B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.6M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | $-8.9M | $68.0M |
| 自由现金流率自由现金流/营收 | -3.7% | 17.7% |
| 资本支出强度资本支出/营收 | 1.0% | 4.8% |
| 现金转化率经营现金流/净利润 | -0.19× | 1.83× |
| 过去12个月自由现金流最近4个季度 | $107.0M | $174.9M |
8季度趋势，按日历期对齐
经营现金流ACLSPEN
| Q4 25 | $-6.6M | $86.5M | ||
| Q3 25 | $45.4M | $58.3M | ||
| Q2 25 | $39.7M | $44.9M | ||
| Q1 25 | $39.8M | $49.0M | ||
| Q4 24 | $12.8M | $51.1M | ||
| Q3 24 | $45.7M | $56.5M | ||
| Q2 24 | $40.1M | $22.6M | ||
| Q1 24 | $42.2M | $38.3M |
自由现金流ACLSPEN
| Q4 25 | $-8.9M | $68.0M | ||
| Q3 25 | $43.3M | $42.0M | ||
| Q2 25 | $37.7M | $29.4M | ||
| Q1 25 | $34.8M | $35.5M | ||
| Q4 24 | $8.1M | $45.7M | ||
| Q3 24 | $41.8M | $51.0M | ||
| Q2 24 | $38.1M | $18.1M | ||
| Q1 24 | $40.6M | $32.5M |
自由现金流率ACLSPEN
| Q4 25 | -3.7% | 17.7% | ||
| Q3 25 | 20.3% | 11.8% | ||
| Q2 25 | 19.4% | 8.7% | ||
| Q1 25 | 18.1% | 11.0% | ||
| Q4 24 | 3.2% | 14.5% | ||
| Q3 24 | 16.3% | 16.9% | ||
| Q2 24 | 14.8% | 6.0% | ||
| Q1 24 | 16.1% | 11.7% |
资本支出强度ACLSPEN
| Q4 25 | 1.0% | 4.8% | ||
| Q3 25 | 0.9% | 4.6% | ||
| Q2 25 | 1.0% | 4.6% | ||
| Q1 25 | 2.6% | 4.2% | ||
| Q4 24 | 1.8% | 1.7% | ||
| Q3 24 | 1.5% | 1.8% | ||
| Q2 24 | 0.8% | 1.5% | ||
| Q1 24 | 0.6% | 2.1% |
现金转化率ACLSPEN
| Q4 25 | -0.19× | 1.83× | ||
| Q3 25 | 1.75× | 1.27× | ||
| Q2 25 | 1.27× | 0.99× | ||
| Q1 25 | 1.39× | 1.25× | ||
| Q4 24 | 0.26× | 1.52× | ||
| Q3 24 | 0.94× | 1.91× | ||
| Q2 24 | 0.79× | — | ||
| Q1 24 | 0.82× | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLS
| Products | $224.6M | 94% |
| Services | $13.7M | 6% |
PEN
| Thrombectomy | $254.7M | 66% |
| Other | $130.7M | 34% |
